Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024

The global paroxysmal nocturnal hemoglobinuria (pnh) market has grown rapidly in recent years. It will grow from $3.84 billion in 2023 to $4.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.

The global paroxysmal nocturnal hemoglobinuria (pnh) market is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

The growing prevalence of blood and bone marrow disorders is set to be a significant driver for the paroxysmal nocturnal hemoglobinuria (PNH) market's expansion in the coming years. Blood disorders encompass a range of medical conditions that affect the composition, function, and production of blood and its various components. Bone marrow-related disorders, on the other hand, occur when the bone marrow either inadequately produces red blood cells, white blood cells, or platelets or generates blood cells that are flawed or damaged. PNH is intricately linked to both blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function, and the bone marrow microenvironment. It is a rare blood disorder closely associated with bone marrow failure diseases, arising from a genetic anomaly that alters the functioning of red blood cells and platelets. For instance, in June 2021, as reported by the Leukemia Foundation, a non-governmental organization based in Australia, over 110,000 individuals in Australia are affected by blood disorders. Projections indicate that the number of Australians with blood disorders will surge to more than 275,000 by 2035. Furthermore, the Cancer Data in Australia 2021 report by the Australian Institute of Health and Welfare (AIHW), a government agency, revealed that over 50 Australians were diagnosed with blood cancer daily in 2021, up from 47 daily diagnoses in 2020. Hence, the increasing incidence of blood disorders and bone marrow-related disorders is a major factor propelling the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

The growing requirement for blood transfusions is poised to be a driving force behind the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood transfusion is a medical procedure that involves the transfer of blood or blood products from a donor to a recipient. For individuals with paroxysmal nocturnal hemoglobinuria (PNH), blood transfusions can offer temporary relief from the symptoms and complications associated with this condition. For instance, in June 2023, the World Health Organization, an intergovernmental organization headquartered in Switzerland, reported that high-income nations, which account for only 16% of the global population, contributed significantly to blood donations, comprising 40% of the total 118.5 million blood donations made worldwide. Additionally, in December 2022, the Government of Canada reported that the United Kingdom experienced an upsurge in blood donations, with 1.7 million donations made across the country in 2021. Consequently, the escalating demand for blood transfusions is a key factor driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

The growth of the paroxysmal nocturnal hemoglobinuria (PNH) market is being constrained by the high costs associated with treatments during the projected period. The substantial expenses related to treatment can dissuade pharmaceutical companies from investing in the development of new and more cost-effective PNH treatments. This could potentially decelerate progress and innovation in the field. For example, according to the American Hospital Association, a professional organization, there was a 2.1% increase in hospital prices in the year leading up to February 2022. As a result, the elevated treatment costs are acting as an impediment to the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Prominent companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are dedicated to the development of novel drugs and therapies to maintain their position in the market. Innovation in treatment options is essential in addressing the unique needs of PNH patients, exemplified by EMPAVELI, the first C3-targeted therapy. For instance, in May 2021, Apellis Pharmaceuticals Inc., a US-based biopharmaceutical company, announced the approval of EMPAVELI (pegcetacoplan) by the U.S. Food and Drug Administration (FDA). EMPAVELI represents the first and only targeted C3 therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). It has the potential to significantly enhance the quality of life for PNH patients by increasing hemoglobin levels and reducing the necessity for blood transfusions. EMPAVELI's benefits extend to adults with PNH, including those transitioning from any C5 inhibitor, as well as patients who have not previously received treatment. To further support patients throughout their treatment journey, the company has introduced ApellisAssist, a treatment access and support program. This program offers a comprehensive range of product support services, including assistance with insurance, educational resources, training, and financial aid for eligible patients.

In July 2021, AstraZeneca PLC, a pharmaceutical company headquartered in the UK, completed the acquisition of Alexion Pharmaceuticals Inc. The financial details of the deal were not disclosed. With this strategic move, AstraZeneca solidifies its position as a leader in the development of medications for individuals affected by rare diseases. This acquisition significantly enhances AstraZeneca's scientific footprint in the field of immunology. Alexion Pharmaceuticals Inc., the company acquired by AstraZeneca, is based in the United States and specializes in research, development, and treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Major players in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd, F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd, Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2023. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the paroxysmal nocturnal hemoglobinuria (PNH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary approaches to treating paroxysmal nocturnal hemoglobinuria (PNH) involve the use of medications, bone marrow transplantation, blood transfusion, immunosuppressive therapy, and other methods. Medications are substances specially designed and formulated for the diagnosis, treatment, prevention, or alleviation of medical conditions, diseases, or symptoms in both humans and animals. Various diagnostic techniques, such as flow cytometry and high-resolution mass spectrometry, are utilized by a range of end users, including hospitals, clinics, and others.

This report provides paroxysmal nocturnal hemoglobinuria market statistics, including paroxysmal nocturnal hemoglobinuria industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria market share, detailed paroxysmal nocturnal hemoglobinuria market segments, market trends and opportunities and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria industry. This paroxysmal nocturnal hemoglobinuria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.